Study of Anti-PD-1 Antibody SHR-1210 Plus Nimotuzumab in the Treatment of Advanced Esophageal Squamous Cell Carcinoma

Phase 2 Unknown 45 enrolled The First Affiliated Hospital of Zhengzhou University

NaSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to observe and evaluate the efficacy and safety of anti-PD-1 antibody SHR-1210 combined with nimotuzumab as second-line therapy in patients with advanced cancerous esophageal squamous cell carcinoma.

Timeline

Start: 2021-09
Primary completion: 2022-12
Completion: 2023-09

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Camrelizumab	Monoclonal antibody	200 mg	Intravenous
Subject	Nimotuzumab	Monoclonal antibody	200 mg	Intravenous

Study of Anti-PD-1 Antibody SHR-1210 Plus Nimotuzumab in the Treatment of Advanced Esophageal Squamous Cell Carcinoma

Summary

Timeline

Drugs

Indications